Inactivating mutations in large B-cell lymphoma in a real-world cohort: Strong correlation with translocation.

Inactivating mutations in Bruton's tyrosine kinase () in patients with follicular lymphoma (FL) have recently been reported. These mutations were found in BTK inhibitor-treatment naïve patients. Here, we report the mutation status in a real-world cohort of patients with non-Hodgkin lymphoma. We found primary mutations in 7.7% of patients with large B-cell lymphoma (LBCL) and in 14.1% of patients with FL. All patients with -mutated LBCL were translocation positive, and the correlation between translocation and mutation persisted even when patients with known transformation from FL were excluded.